Takeda provides update on tak-994 clinical program

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that a safety signal has emerged in phase 2 studies of tak-994, an investigational oral orexin agonist. as an immediate precautionary measure, the company has suspended dosing of patients and has decided to stop both phase 2 studies early. this allows for the timely interpretation of the benefit /risk profile of tak-994 and to determine next steps for the progra
TAK Ratings Summary
TAK Quant Ranking